Anti BCMA CAR T cell therapy - Juno Therapeutics

Drug Profile

Anti BCMA CAR T cell therapy - Juno Therapeutics

Alternative Names: Anti-BCMA CAR - Juno Therapeutics; Anti-BMCA Chimeric antigen receptor cell therapy-Juno Therapeutics; BCMA-CAR-T-Juno Therapeutics; BCMA-specific CAR expressing T-Lymphocytes-Juno Therapeutics; BCMA-specific CAR-T-Juno Therapeutics; BCMA-Targeted CAR-T Cells-Juno Therapeutics; EGFRt/BCMA 41BBz CAR-T cell; ET 140; ET140 CAR; FCARH143; JCARH-125; MCARH171

Latest Information Update: 09 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Juno Therapeutics
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Multiple myeloma

Most Recent Events

  • 06 Mar 2018 Juno Therapeutics has been acquired by Celgene Corporation
  • 01 Feb 2018 Phase-I/II clinical trials in Multiple myeloma (Second-line therapy or greater) in USA (IV) (NCT03430011)
  • 11 Dec 2017 Safety and efficacy data from a phase I trial in Multiple myeloma presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top